Aeterna Zentaris (AEZS) Enters Collaboration with Ventana Medical for LHRH Development

Aeterna Zentaris Inc. (Nasdaq: AEZS) has entered into a collaboration agreement with Ventana Medical Systems, Inc., a member of the Roche Group (OTCBB: RHHBY), to develop a companion diagnostic for the immunohistochemical determination of luteinizing hormone-releasing hormone (LHRH) receptor expression, for the Company's doxorubicin LHRH targeted conjugate compound, AEZS-108. In humans, LHRH receptors are expressed in a significant proportion of endometrial, ovarian, breast, bladder, prostate and pancreatic tumors. AEZS-108 specifically targets LHRH receptors and therefore, could prove to be more efficient in treating patients with these types of LHRH-receptor positive cancers. Phase 2 trials with AEZS-108 for LHRH-receptor positive advanced endometrial and ovarian cancer have recently been successfully completed.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Agenus drug combo shows 33% three-year survival in colorectal cancer
• Zentek shares to move from Nasdaq to OTC Markets on Sept. 2
• Roche wins FDA nod for HER2 companion diagnostics in GEA